You are here

Article Text

Article menu
Download PDFPDF
Therapeutics
Review: vaccines against human papillomavirus prevent cervical cancer precursors in young women for at least 3 years

https://doi.org/10.1136/ebm.12.6.168

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Do vaccines against human papillomavirus (HPV) prevent HPV 16/18 related cervical intraepithelial neoplasia grade 2 or 3 (CIN 2/3) and adenocarcinoma in situ (AIS) in young women?

    Ault KA, for the Future II Study Group. Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials. Lancet 2007;369:1861–8.

    Clinical impact ratings GP/FP/Primary care ★★★★★★⋆ Gynaecology ★★★★★★⋆ Public health ★★★★★★⋆

    METHODS

    Embedded ImageDesign:

    prespecified combined analysis of 4 randomised controlled trials.

    Embedded ImageAllocation:

    concealed.*

    Embedded ImageBlinding:

    blinded (clinicians, participants, outcome assessors, and adjudication committee).*

    Embedded ImageFollow-up period:

    mean 3 years (maximum 4 y). Follow-up started on day 1 in the intention-to-treat and susceptible populations and 1 month after the third dose of vaccine in the per protocol population.

    Embedded ImageSetting:

    clinics in North America, Latin America, …

    View Full Text

    Footnotes

    • Source of funding: Merck Research Laboratories.